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Abstract
Background—The World Health Organisation recommends continuation with the failing 
second-line regimen if third-line option is not available. We investigated treatment outcomes 
among people living with HIV in Asia who continued with failing second-line regimens compared 
to those who had treatment modifications after failure.
Methods—Treatment modification was defined as a change of two antiretrovirals, a drug class 
change, or treatment interruption (TI), all for >14 days. We assessed factors associated with CD4 
changes and undetectable viral load (UVL <1000 copies/mL) at one year after second-line failure 
using linear and logistic regression, respectively. Survival time was analysed using competing risk 
regression.
Results—Of the 328 patients who failed second-line ART in our cohorts, 208 (63%) had a 
subsequent treatment modification. Compared to those who continued the failing regimen, the 
average CD4 cell increase was higher in patients who had a modification without TI 
(difference=77.5, 95%CI 35.3-119.7) while no difference was observed among those with TI 
(difference=−5.3, 95%CI −67.3-56.8). Compared to those who continued the failing regimen, the 
odds of achieving UVL was lower in patients with TI (OR=0.18, 95%CI 0.06-0.60) and similar 
among those who had a modification without TI (OR=1.97, 95%CI 0.95-4.10), with proportions of 
UVL 60%, 22% and 75%, respectively. Survival time was not affected by treatment modifications.
Conclusion—CD4 cell improvements were observed in those who had treatment modification 
without TI compared to those on the failing regimen. When no other options are available, 
maintaining the same failing ART combination provided better VL control than interrupting 
treatment.
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Introduction
With expanded access of antiretroviral therapy (ART), increase in viral load (VL) 
monitoring and longer duration of ART exposure in people living with HIV (PLHIV), it is 
expected that first- and second-line treatment failure will subsequently increase due to the 
emergence of drug resistance and suboptimal ART adherence(1–3). The mortality rate after 
second-line failure is high(4), which raises concerns regarding access and availability to 
third-line therapy.
The World Health Organization (WHO) estimates that less than 1% of PLHIV on ART are 
currently taking third-line regimen. It recommends that third-line regimens should include 
new drugs such as integrase inhibitors (raltegravir), or second generation non-nucleotide 
reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) such as darunavir and 
etravirine. If there are no new ART options, patients are recommended to continue with a 
tolerated regimen(5). The cost of third-line regimens are higher than first- or second-line, 
limiting their availability in resource-limited countries(6, 7).
At the time when the WHO began recommending PI combinations as treatment options for 
second-line therapy (8, 9), the drug combination was not readily accessible in low-income 
settings due to the high cost of PIs. In the Asia-Pacific region, a previous study of the 
TREAT Asia HIV Observational Database (TAHOD) reported half of PLHIV enrolled in the 
cohort who had failed first-line ART remained on the failing regimen for the first year 
following treatment failure. Those from low income sites were less likely to switch soon 
after failure due to limited access to the newer PI-based second-line combination (10). Once 
second-line ART became more widely available in the Asia-Pacific, the high cost of 
switching to third-line ART became the next barrier in the long term management of HIV. In 
Myanmar, where routine VL testing is not readily available, of the 824 PLHIV receiving 
second-line regimen, 6% had VL testing and 37% of those tested had VL failure. None of 
the PLHIV with VL failure were switched to third-line ART(11). However, an Indian cohort 
study of PLHIV failing second-line ART found that 62% of those who had failed had been 
able to achieve undetectable VL after enhanced adherence support whilst remaining on 
second-line regimen, and therefore avoided the unnecessary switch to a more expensive 
third-line ART regimen(3).
As the number of PLHIV failing second-line ART is expected to increase, we aimed to 
investigate treatment modifications after second-line failure among PLHIV in Asia, and 
treatment outcomes among those who remained on the failing second-line regimen 
compared to those who had a treatment modification.
Methods
Study population
PLHIV enrolled in two Asia-Pacific adult HIV observational cohorts: (i) TAHOD, and (ii) 
TAHOD – Low Intensity Transfer (TAHOD-LITE), who failed second-line ART were 
included. We included TAHOD patients enrolled between 2003 to 2018, and TAHOD-LITE 
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patients from the 2017 cohort. Cohort profiles have been described elsewhere(12, 13), but 
briefly TAHOD enrolment began in 2003 and currently recruits PLHIV from 21 sites in 12 
countries in Asia. TAHOD-LITE was initiated in 2014 and is a sub-study of TAHOD that 
collects more limited HIV clinical data on all patients at participating sites. The most recent 
TAHOD-LITE cohort (2017 cohort) included 10 of the 21 TAHOD sites.
Definitions
Second-line ART was defined as a change of two drugs or a drug class change from the 
initial first-line combination, within six months of first virological, immunological or 
clinical failure. Delayed ART switches after six months were excluded to avoid including 
switches due to other reasons such as adverse events. Treatment failures were defined 
according to WHO 2016 guidelines(5) and adapted to our cohort settings where VL is 
performed annually at most sites. Virological failure in this study was defined as a single 
measurement of VL ≥1000 copies/ml after 6 months on ART. A secondary VL confirmation 
was not required to define VL failure as many of our sites do not perform repeat VL testing 
after the first evidence of VL ≥1000 copies/ml. Immunological failure was defined as 
persistent (two consecutive measurements within 6 months) CD4 cell count <100 cells/uL 
after 6 months on ART. As our cohort collected Centre for Disease Control (CDC) disease 
grading rather than WHO staging, clinical failure in this study was defined as having a CDC 
grade C diagnosis after 6 months on ART. If multiple failure events occurred, the first failure 
event was used.
Second-line ART failure was defined as having a virological, immunological or clinical 
failure event after having been on second-line therapy for at least six months. Treatment 
modification after second-line failure was defined as a change of two drugs or a drug class 
change, including treatment interruption. Treatment modification of less than 14 days was 
not included. Those with treatment modification were further categorised according to their 
treatment interruption status in each analysis.
Statistical analyses
Factors associated with CD4 changes and undetectable VL at one year after second-line 
ART failure (within +/− six months window period) were analysed using linear regression 
and logistic regression, respectively. CD4 change was defined as a difference between CD4 
count at one year after second-line failure and the CD4 measurement taken at the time of 
second-line failure. Undetectable VL was defined as VL<1000 copies/mL. PLHIV without 
CD4 or VL measurement at one year (+/− six months) were not included in the CD4 or the 
VL analysis. Treatment modification variable was categorised as (i) no, (ii) yes, without 
treatment interruption and (iii) at least 1 treatment interruption, within the first year after 
second-line failure. Other variables included were age at second-line ART failure, sex, mode 
of HIV exposure, VL and CD4 at time of second-line failure, ART duration, ART regimen at 
second-line failure, hepatitis B/C co-infection defined as positive hepatitis B surface antigen 
and positive hepatitis C antibody respectively, prior AIDS diagnosis defined as a CDC grade 
C disease category, and World Bank country income level group (14).
Jiamsakul et al. Page 4
Antivir Ther. Author manuscript; available in PMC 2021 July 12.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Survival time from second-line failure was analysed using Fine and Gray’s competing risk 
regression, with loss to follow-up (LTFU) included as a competing risk. Risk time for 
mortality began on the date of second-line failure and ended on the date of death or date of 
last follow-up. Time updated variables included were treatment modification, VL, CD4 and 
ART duration. Treatment modification was coded as a time-updated variable to account for 
variation in ART combinations, for example, a patient could have treatment interruption then 
resume with the same regimen taken at time of second-line failure. Other variables were 
analysed as time-fixed covariates. World Bank country income was adjusted as a priori to 
account for differences in third-line ART availability.
Regression models were fitted using backward stepwise procedures. Factors significant in 
univariate analyses with p<0.10 were included in the multivariate analyses. Factors with 
p<0.05 in the final multivariate model were considered statistically significant. The effects 
of other non-significant factors were presented adjusting for the significant predictors, 
however they did not form part the final multivariate model. Ethics approvals were obtained 
from the local ethics committees of all participating sites, the data management and 
biostatistical center (The Kirby Institute, UNSW Sydney), and the coordinating centre 
(TREAT Asia/amfAR). Data management and statistical analyses were performed using 
SAS software version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata software version 
14.2 (Stata Corp., College Station, TX, USA).
Results
There were 328 patients from Cambodia, China, Hong Kong SAR, India, Indonesia, Japan, 
South Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam, who 
failed second-line ART according to our definition of treatment failure. There were 146 
patients who had more than one type of failures resulting in 295 virological failures; 140 
immunological failures; and 57 clinical failures, from our cohort of 328 patients.
The median age at second-line failure was 39.5 years (interquartile range (IQR) 34-56), with 
79% being male. The median CD4 cell count was 209 cells/μL (IQR 85-359) and the median 
VL was 12917 copies/mL (IQR 3040-81900). Of the 328 patients, the median time on 
second-line ART was 1.19 years (IQR 0.72-2.62), and 208 (63%) had at least one treatment 
modification after second-line ART failure, including treatment interruption (Table 1).
Of the 208 patients who had a treatment modification, the initial ART combinations that 
these patients were modified to after second-line failure were: NRTI + PI (118/208, 57%), 
integrase inhibitor (INSTI)-based combination (any ART combination containing INSTI) 
(26/208, 13%), NRTI + NNRTI (12/208, 6%) and other ART combinations (15/208, 7%). 
There were 37/208 patients (18%) who had treatment interruption. INSTI-based 
combination comprised of raltegravir (22 patients, 85%) and dolutegravir (4 patients, 15%).
Changes in CD4 cell count
There were 230 patients who had a CD4 measurement available one year after second-line 
ART failure, and were included in the analysis. The mean CD4 cell increase at one year was 
56.5 cells/μL (95%CI 37-76). Patients who did not have a treatment modification in the first 
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year after second-line ART failure had a mean CD4 cell increase of 31.4 cells/μL (95%CI 
8-54). Those who had a treatment modification without treatment interruption had a mean 
CD4 cell increase of 111.6 (95%CI 77-147), while those who had at least one treatment 
interruption in the first year had an average increase of 41.1 cells/μL (95%CI −40-122). The 
univariate analysis in Table 2 shows that factors associated with CD4 cell increase were 
treatment modification (p=0.001) and CD4 count at second-line failure (p=0.004). The 
multivariate analysis indicates those who had a treatment modification without interruption 
had a higher increase in CD4 count at one year after second-line failure compared to those 
who did not have a treatment modification (difference=77.5, 95%CI 35.3-119.7, p<0.001), 
while no differences were observed among those who had at least one treatment interruption 
(difference=−5.3, 95%CI −67.3-56.8, p=0.867). Those who had a CD4 cell count >500 cells/
μL at time of second-line failure had a significant reduction in CD4 count at one year 
compared to those who failed at CD4 ≤200 cells/μL (difference=−121.4, 95%CI −196.2 to 
−46.6, p=0.002). Country income was not associated with changes in CD4 cell count 
(p=0.060), but was adjusted in the multivariate analysis.
Undetectable VL
Of the 189 patients who had a VL measurement, 115 (61%) were undetectable at one year 
after second-line ART failure (Table 3). There were 118/189 patients (62%) who did not 
have treatment modification in the first year after second-line ART failure, of which 71 
(60%) had undetectable VL. Of the 53 patients who had treatment modification without 
treatment interruption, 40 (75%) achieved VL suppression. The proportion with undetectable 
VL was lowest for the group who had interrupted treatment at least once, 4/18 (22%).
Adjusting for country income level, patients who had treatment interruption at least once 
during the first year after second-line failure were less likely to achieve undetectable VL 
compared to those who had remained on the failing regimen (OR=0.18, 95%CI 0.06-0.60, 
p=0.005). Those who had a treatment modification without an interruption showed no 
differences in the odds for achieving undetectable VL (OR=1.97, 95%CI 0.95-4.10, 
p=0.069). No other factors were associated with undetectable VL at one year after second-
line ART failure.
Survival
There were 39 deaths from 328 patients (12%) after second-line ART failure (Table 4). The 
median follow-up time from second-line failure was 2.8 years (IQR 1.2-5.2). The overall 
mortality rate was 3.2 per 100 person-years (/100PYS). The mortality rate among patients 
who did not currently have a treatment modification was 3.9/100PYS while those who had a 
modification but were currently on ART had a rate of 3.0/100PYS. No deaths occurred 
during periods of treatment interruption (p log-rank = 0.182) (Figure 1). There were 61 
patients (19%) who became LTFU after second-line failure. These LTFU patients were 
included as competing risk in the analysis. In multivariate analysis, factors associated with 
mortality were older age >50 years (SHR=4.20, 95%CI 1.94-9.11, p<0.001) compared to 
age 31-40 years, and injecting drug use as a mode of HIV exposure (SHR=5.29, 95%CI 
1.73-16.15, p=0.003). Higher CD4 counts (351-500 cells/μL: SHR=0.12, 95%CI 0.03-0.50, 
p=0.004; and >500 cells/μL: SHR=0.06, 95%CI 0.01-0.54, p=0.012) compared to CD4 ≤200 
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cells/μL were associated with improved survival. Treatment modification was not associated 
with differences in survival.
Discussion
In our cohort of PLHIV in the Asia-Pacific, more than half of those who failed second-line 
ART had a subsequent treatment modification. Most patients received NRTI+PI regimen at 
time of second-line failure and a small proportion were switched to an INSTI-based 
regimen. The average CD4 cell increase at one year post second-line failure was 
significantly higher in those that had a treatment modification without treatment 
interruption, than those who did not have a modification. No significant differences in CD4 
changes were observed among those who had at least one interruption. Achieving 
undetectable VL following second-line failure was less likely for those who had interrupted 
treatment at least once compared to those who remained on the failing second-line regimen. 
Survival was not associated with treatment modification.
Availability of different ART combinations is often limited in resource-poor settings in the 
Asia-Pacific region. As second-line ART options are not readily available among some of 
our sites, and with limited access to INSTI-containing regimens, switching to third-line ART 
combinations may not be a feasible option in our setting. Although more than half of our 
patients had a treatment modification, only a small proportion had switched to one of the 
WHO recommended INSTI-based dolutegravir or raltegravir- combination ART regimens 
(5). A South African study reported approximately 5% of PLHIV who have failed second-
line ART had switched to third-line. Of those who had switched, almost half had switched to 
a raltegravir-containing regimen (15).
CD4 cell increase after second-line failure was higher in those who had a treatment 
modification without treatment interruption, compared to those who did not have a treatment 
modification. This is consistent with findings where those who had a delayed switch 
experienced worst immunological outcomes (16). However, no differences were observed in 
the proportion with undetectable VL between these two sub-groups. Overall, 60% of our 
study population had undetectable VL at one year after second-line failure. Other studies in 
resource-limited settings have reported varying proportions of undetectable VL ranging from 
64% to 93%(1, 17, 18), although it is worth noting that different definitions of undetectable 
VL were adopted in these studies. We also found that although there were no significant 
difference between those on ART who had treatment modification compared to those who 
did not, patients who had treatment interruption in the first year after second-line failure 
were less likely to achieve undetectable VL compared to patients who did not have a 
modification. This emphasises the importance of maintaining continuous second-line 
therapy when no feasible third-line options are available. Prior to the availability of current 
third-line regimens, patients failing second-line ART were maintained on the failing 
regimen, raising concerns regarding possible development of drug resistance mutations due 
to prolonged viral failure (19). A Uganda study found up to 19% of patients failing second-
line had a major PI mutation and 83% had an NRTI mutation, with a median time of 29 
months on second-line therapy (20). However, it is important to differentiate between ART 
failure due to drug resistance and failure due to poor adherence (21) as proper adherence 
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intervention strategies can effectively lead to VL re-suppression, thus avoiding unnecessary 
switch to third-line therapy (20, 22, 23). Although we did not include adherence or drug 
resistance as risk factors due to data not being collected in one or both of our cohorts, results 
from these studies suggest the importance of remaining on ART to achieve optimal VL 
response further reinforcing our findings of poor VL outcomes in those who had treatment 
interruption compared to those who remained on the failing regimen.
Survival time was associated with traditional risk factors such as age, mode of HIV exposure 
and CD4 cell count. There was no association between treatment modification and 
subsequent survival. There is limited literature comparing survival outcomes after second-
line treatment failure, however studies have reported up to 26% mortality among those who 
have failed but remained on second-line (11) and 5-11% among those who have switched to 
third-line (3, 15, 24, 25). Our study observed a mortality rate of 3.9/100PYS for those who 
did not have a treatment modification, and 3.0/100PYS for those who did without ART 
interruption. Delayed switch from first-line to second-line ART has been shown to be 
associated with increased mortality in resource-limited settings (26, 27). This study observed 
no differences in survival outcomes after second-line ART failure, however the benefits of 
treatment modification were seen with greater CD4 increase in those who had their 
treatment modified without interruption, while those who had treatment interruption were 
less likely to achieve undetectable VL compared to those who remained on the same failing 
second-line regimen.
There are several limitations to the study. We defined virologic failure as a single VL 
measurement ≥1000 copies/mL without a second confirmatory test. We adopted this 
approach as VL testing in many of our sites is conducted on an annual basis. Although using 
this definition could lead to an over estimation of virological failure, it does allow for 
capture of all potential virological failures and assessment of any subsequent treatment 
change. Although adherence has been shown to be an important predictor of treatment 
outcomes amongst patients who have failed second-line ART, we did not adjust for ART 
adherence. Our TAHOD-LITE cohort does not collect ART adherence, as such we were 
unable to control for the confounding effects of adherence in our analyses. Drug resistance 
information was not available in our two cohorts further limiting the assessment of its 
association with treatment failure. We defined treatment modification as a change of two 
drugs or a drug class change from second-line ART. This definition did not specifically 
include a switch to dolutegravir or raltegravir due to limited availability of integrase 
inhibitors in our region. Finally, the small number of patients included in this analysis does 
not allow us to make inference about the effects of treatment modification following second-
line failure in the general PLHIV population in Asia.
Conclusions
Improved immunological outcomes were observed among PLHIV who had failed second-
line ART and had a subsequent treatment modification without treatment interruption. There 
were no differences in mortality, however undetectable VL was less likely to be achieved if 
ART was interrupted compared to those who remained on the failing regimen. These 
findings indicate that maintaining patients on the same second-line ART combination 
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provided better VL control than having treatment interruption, further reinforcing the WHO 
recommendations of continuation with the well tolerated regimen when no other third-line 
treatment options are available.
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Figure 1: 
Survival time from second-line ART failure by current treatment modification status
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Table 1:
Patient characteristics
Total patients (%)
Total with treatment modification, including 
treatment interruption (%)
Total 328 (100) 208 (63)
Age at second-line ART failure (years) Median = 39.5, IQR (34-46) Median = 39, IQR (35-45)
≤30 39 (12) 22 (11)
31-40 146 (45) 99 (48)
41-50 93 (28) 60 (29)
>50 50 (15) 27 (13)
Sex
Male 258 (79) 171 (82)
Female 70 (21) 37 (18)
HIV mode of exposure
Heterosexual contact 243 (74) 155 (75)
MSM 50 (15) 32 (15)
Injecting drug use 9 (3) 5 (2)
Other/Unknown 26 (8) 16 (8)
Viral Load at second-line failure (copies/mL) Median = 12917, IQR (3040-81900) Median = 12558, IQR (3146-64148)
<1000 13 (4) 8 (4)
≥1000 258 (79) 160 (77)
Not tested 57 (17) 40 (19)
CD4 at second-line failure (cells/μL) Median = 209, IQR (85-359) Median = 205, IQR (86-336)
≤200 148 (45) 97 (47)
201-350 80 (24) 55 (26)
351-500 55 (17) 34 (16)
>500 23 (7) 11 (5)
Not tested 22 (7) 11 (5)
ART duration (years)
<5 182 (55) 122 (59)
5 to <10 117 (36) 72 (35)
≥ 10 29 (9) 14 (7)
ART Regimen at second-line failure
NRTI+NNRTI 55 (17) 41 (20)
NRTI+PI 240 (73) 144 (69)
Other combination 33 (10) 23 (11)
Hepatitis B co-infection
Negative 208 (63) 135 (65)
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Total patients (%)
Total with treatment modification, including 
treatment interruption (%)
Total 328 (100) 208 (63)
Positive 17 (5) 11 (5)
Not tested 103 (31) 62 (30)
Hepatitis C co-infection
Negative 177 (54) 121 (58)
Positive 15 (5) 7 (3)
Not tested 136 (41) 80 (38)
Prior AIDS Diagnosis
No 46 (14) 25 (12)
Yes 78 (24) 53 (25)
Not reported 204 (62) 130 (63)
World Bank country income level
Lower bottom 193 (59) 118 (57)
Upper bottom 40 (12) 26 (13)
High 95 (29) 64 (31)
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